

Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
2022-08-18 | NDAQ:BCRX | Press Release | BioCryst Pharmaceuticals Inc. | stockhouse.com • |
Russell Investments Group Ltd. Has $1.31 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) | defenseworld.net • |
BioCryst Pharmaceuticals Inc (BCRX) Down 3.35% in Premarket Trading | investorsobserver.com • |
Ginkgo Bioworks Holdings Inc (DNA) Down 3.48% in Premarket Trading | investorsobserver.com • |
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia | marketscreener.com • |
State Board of Administration of Florida Retirement System Sells 13040 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) | defenseworld.net • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-08-04 | 2022-06 | -0.36 | -0.32 | 0.04 | 11.11% |
2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-08-08 | Oppenheimer | Downgrade | Outperform | Perform |
2022-08-05 | Barclays | Upgrade | Equal-Weight | |
2022-08-05 | Oppenheimer | Downgrade | Outperform | Perform |
2022-08-05 | Evercore ISI Group | Downgrade | Outperform | In-Line |
2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
2022-04-12 | RBC Capital | Upgrade | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
2022-06-06 | HEGGIE THERESA | Director | 30.23K | Stock Award(Grant) |
2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
2022-06-06 | INGRAM ROBERT ALEXANDER | Director | 95.00K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-06-29 | Blackrock Inc. | 13.99M | 199.32M | 7.52% |
2022-06-29 | Vanguard Group, Inc. (The) | 13.81M | 196.79M | 7.43% |
2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 181.13M | 6.84% |
2022-03-30 | State Street Corporation | 7.46M | 106.34M | 4.01% |
2022-06-29 | Pictet Asset Management SA | 6.05M | 86.17M | 3.25% |
2022-06-29 | Fisher Asset Management, LLC | 5.22M | 74.34M | 2.81% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-06-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 7.26M | 103.50M | 3.91% |
2022-03-30 | Vanguard Total Stock Market Index Fund | 5.26M | 74.97M | 2.83% |
2022-06-29 | iShares Russell 2000 ETF | 4.17M | 59.43M | 2.25% |
2022-05-30 | Fidelity Select Portfolios - Biotechnology | 4.19M | 59.74M | 2.25% |
2022-04-29 | Lord Abbett Developing Growth Fund | 2.45M | 34.94M | 1.32% |
2022-03-30 | Vanguard Extended Market Index Fund | 2.39M | 34.03M | 1.29% |
Dividend | Date |
---|---|
0 | 2014-06-11 |
0 | 2014-06-05 |
0 | 2014-05-20 |
0 | 2014-05-16 |
0 | 2014-04-02 |
-
The highest this DD stock has ever been is 6.29. Needs life support at this point. Maybe the Tutes can afford to wait years on end because it’s manipulated daily and they still make money.
-
Please BCRX throw us a bone, this is crazy now
-
Time to make a decision soon, worn out. Too predictable and no news.
-
Another day another disappointment
-
This is sad. Only news I see is July 3 changed to a hold
-
I’m still waking up, but so far I see no news on this one today. I see lots of news on others tho. I’ll hope for the best.
-
Some people say possibly $200, I could live with that.
-
How much can this stock realistically rise? I’ve read here anywhere from $25-200. I’ve done the math on all. 🤔🤑
-
Such a tease. Maybe next 2 weeks?
-
Maybe next week. Oh well
-
Everything Green but BCRX News please!
-
What the heck is going on? They manipulate it constantly day in and day out.
-
BioBoom have you nothing better to do than kick people down? Is that what makes you happy, really?
-
Selling at cost if I make it, will rebuy at the dip. This is not exploding anytime soon. Feeling done.
-
Something is very wrong with this picture. Giving this a 2 week deadline.
-
Still no news and dragging on. More of the same.
-
To Alan. Have you ever seen this before where a stock is majority institute owned and it’s manipulated like this? Ive only been in trading under a year. Just trying to learn. Tysm
-
Is bcrx The Sleeping Giant ? Why is there not one bit of news? It’s in a coma.
-
Today may not be the day. I was unhappy with this stock before but holding out hope based on the hints of better days. Not selling and might buy more on the dips. GL to all.
-
Order in for 4.78 let’s see if the line grabs it.
-
BioCryst Pharmaceuticals Inc (BCRX) Down 3.35% in Premarket Trading
investorsobserver.com • -
Ginkgo Bioworks Holdings Inc (DNA) Down 3.48% in Premarket Trading
investorsobserver.com • -
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
marketscreener.com • -
Top 5 2nd Quarter Trades of Biondo Investment Advisors, LLC
gurufocus.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com • -
7 A-Rated Biotech Stocks to Buy Now
investorplace.com • -
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
seekingalpha.com • -
Is BioCryst a Good Stock to Buy Now?
fool.com • -
BioCryst: Solid Delivery And Follow Through
seekingalpha.com • -
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
globenewswire.com • -
BCRX Stock Price: $15 Target By Piper Sandler
pulse2.com • -
BioCryst Technical Levels To Watch
benzinga.com •